Abstract

The scope of 6,8-dioxa-3-aza-bicyclo(3.2.1)octane derivatives as morpholine replacing groups in bioactive compounds was investigated. Four derivatives were synthesized and subjected to the routinary screening strategy, as part of a project directed to obtain new tachykinin NK2 antagonists. The obtained results encourage further study on the heterobicycle 6,8-dioxa-3-aza-bicyclo(3.2.1)octane as morpholine surrogate.

Keywords: Tachykinins, Neurokinin A, 6,8-dioxa-3-aza-bicyclo(3.2.1)octane, Morpholine, Oligomer